Literature DB >> 27233940

Lobular breast cancer: Clinical, molecular and morphological characteristics.

Matthias Christgen1, Doris Steinemann2, Elna Kühnle3, Florian Länger4, Oleg Gluz5, Nadia Harbeck6, Hans Kreipe4.   

Abstract

Infiltrating lobular breast cancer (ILBC) is the most common special breast cancer subtype. This review provides a comprehensive description of ILBC characteristics, including epidemiology, clinical features, molecular genetics and histomorphology. Twenty detailed supplemental data tables guide through primary data of more than 200 original studies. Meta-analyses indicate that ILBC is at least twice as common in the Western world as it is in other geographic regions. ILBC is over-represented in so-called interval carcinomas and in primary metastatic breast cancer. ILBC is also associated higher age, higher pT stage and hormone receptor (ER/PR) positivity. Pathological complete response rates after neoadjuvant chemotherapy are low, ranging between 0% and 11%. Positive resection margins after breast-conserving surgery are comparatively frequent and 17% to 65% of patients undergo a second surgical intervention. Depending on the morphological stringency in the diagnosis of ILBC, lack of E-cadherin expression is observed in 55% to 100% of cases. CDH1/E-cadherin mutation detection rates vary between 12% and 83%. Various additional molecular factors, including PIK3CA, TP53, FOXA1, FGFR1, ZNF703 and BCAR4, have been implicated in ILBC or progression of lobular carcinoma in situ (LCIS) to invasive cancer and are discussed in detail. Eight instructive figure plates recapitulate the histomorphology of ILBC and its variants. Furthermore, we draw attention to rarely addressed histological details, such as two-sided nuclear compression and fat-avoiding growth at the invasion front. Last but not least, we discuss future translational research directions and emphasize the concept of synthetic lethality, which promises new options for targeted ILBC therapy.
Copyright © 2016. Published by Elsevier GmbH.

Entities:  

Keywords:  Anti-hormone therapy; CDH1; E-cadherin; Lobular breast cancer; Molecular profiling; Resection margins; Screening

Mesh:

Substances:

Year:  2016        PMID: 27233940     DOI: 10.1016/j.prp.2016.05.002

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  34 in total

Review 1.  Comprehensive Review of Molecular Mechanisms and Clinical Features of Invasive Lobular Cancer.

Authors:  Nikhil Pramod; Akanksha Nigam; Mustafa Basree; Resham Mawalkar; Saba Mehra; Neelam Shinde; Gary Tozbikian; Nicole Williams; Sarmila Majumder; Bhuvaneswari Ramaswamy
Journal:  Oncologist       Date:  2021-03-16

2.  SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma.

Authors:  Emily A Bossart; Nilgun Tasdemir; Matthew J Sikora; Amir Bahreini; Kevin M Levine; Jian Chen; Ahmed Basudan; Britta M Jacobsen; Timothy F Burns; Steffi Oesterreich
Journal:  Breast Cancer Res Treat       Date:  2019-02-23       Impact factor: 4.872

3.  Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities.

Authors:  Hillary Stires; Mary M Heckler; Xiaoyong Fu; Zhao Li; Catherine S Grasso; Michael J Quist; Joseph A Lewis; Uwe Klimach; Alan Zwart; Akanksha Mahajan; Balázs Győrffy; Luciane R Cavalli; Rebecca B Riggins
Journal:  Mol Cell Endocrinol       Date:  2017-09-19       Impact factor: 4.102

4.  Perivascular infiltration reflects subclinical lymph node metastasis in invasive lobular carcinoma.

Authors:  Akiko Igawa; Hiroki Mizukami; Kazuhiro Kudoh; Yuki Takeuchi; Takanori Sasaki; Xuekai Pan; Kenichi Hakamada
Journal:  Virchows Arch       Date:  2022-08-10       Impact factor: 4.535

5.  Characteristics of Special Type Breast Tumors in Our Center.

Authors:  Tonguç Utku Yılmaz; Levent Trabzonlu; Sertaç Ata Güler; Mehmet Ali Baran; Gökhan Pösteki; Cengiz Erçin; Zafer Utkan
Journal:  Eur J Breast Health       Date:  2018-01-01

6.  E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

Authors:  Ilirjana Bajrami; Rebecca Marlow; Marieke van de Ven; Rachel Brough; Helen N Pemberton; Jessica Frankum; Feifei Song; Rumana Rafiq; Asha Konde; Dragomir B Krastev; Malini Menon; James Campbell; Aditi Gulati; Rahul Kumar; Stephen J Pettitt; Mark D Gurden; Marta Llorca Cardenosa; Irene Chong; Patrycja Gazinska; Fredrik Wallberg; Elinor J Sawyer; Lesley-Ann Martin; Mitch Dowsett; Spiros Linardopoulos; Rachael Natrajan; Colm J Ryan; Patrick W B Derksen; Jos Jonkers; Andrew N J Tutt; Alan Ashworth; Christopher J Lord
Journal:  Cancer Discov       Date:  2018-04       Impact factor: 39.397

Review 7.  Histology of Luminal Breast Cancer.

Authors:  Ramona Erber; Arndt Hartmann
Journal:  Breast Care (Basel)       Date:  2020-07-15       Impact factor: 2.860

8.  E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors.

Authors:  Eike Burandt; Felix Lübbersmeyer; Natalia Gorbokon; Franziska Büscheck; Andreas M Luebke; Anne Menz; Martina Kluth; Claudia Hube-Magg; Andrea Hinsch; Doris Höflmayer; Sören Weidemann; Christoph Fraune; Katharina Möller; Frank Jacobsen; Patrick Lebok; Till Sebastian Clauditz; Guido Sauter; Ronald Simon; Ria Uhlig; Waldemar Wilczak; Stefan Steurer; Sarah Minner; Rainer Krech; David Dum; Till Krech; Andreas Holger Marx; Christian Bernreuther
Journal:  Biomark Res       Date:  2021-06-05

9.  Invasive lobular carcinoma: clinicopathological features and subtypes.

Authors:  Sabine Danzinger; Nora Hielscher; Miriam Izsó; Johanna Metzler; Carmen Trinkl; Christian Pfeifer; Kristina Tendl-Schulz; Christian F Singer
Journal:  J Int Med Res       Date:  2021-06       Impact factor: 1.671

10.  Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer-An NCDB Analysis (2004-2016).

Authors:  Macy M Goldbach; Laura Burkbauer; Tina Bharani; Austin D Williams; Luke Keele; Jami Rothman; Rachel Jankowitz; Julia C Tchou
Journal:  Ann Surg Oncol       Date:  2021-06-14       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.